Small New World Laboratories develops and manufactures human cell-derived biologics that enhance tissue regeneration while minimizing fibrotic scar formation. Their GMP-compliant processes support contract manufacturing and clinical testing, enabling researchers and commercial entities to advance therapeutic solutions effectively.
Funding
Funding not disclosed
Founders
Product
Problem
The body's natural response to injury often results in fibrotic scar formation, which can impede the natural processes of tissue repair and regeneration, leading to significant healthcare challenges. Current methods may not adequately address the complex interplay of mechanical and biochemical factors that contribute to scarring.
Solution
Small New World Laboratories develops and manufactures human cell-derived biologics designed to enhance tissue regeneration and minimize fibrotic scar formation. Their advanced biologics aim to improve and accelerate the body's endogenous healing process by suppressing inflammatory immunoreactivity and fibrosis. SNWlabs leverages transdisciplinary expertise, scientifically verified solutions, and state-of-the-art equipment to provide innovative solutions for tissue regeneration. They also engage in contract process development and contract manufacturing activities to support basic researchers and commercial entities.
Target Audience
The primary audience includes researchers and commercial entities focused on advancing therapeutic solutions for tissue regeneration and scar reduction.
Features
- GMP-compliant manufacturing in a licensed pharmaceutical environment
- Development of appropriate processes for manufacturing and quality control
- Development of new analytical technologies
- Support for clinical testing of new therapeutic preparations (up to Phase II Clinical Trials)